LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

LLY

713.6

-0.54%↓

JNJ

152.71

+0.53%↑

ABBV

182.24

+0.74%↑

NVO

67.5

+0.28%↑

UNH

297.4

-0.69%↓

Search

ESPERION THERAPEUTICS INC

Abierto

SectorSanidad

0.78 -6.02

Resumen

Variación precio

24h

Actual

Mínimo

0.76

Máximo

0.83

Métricas clave

By Trading Economics

Ingresos

-19M

-40M

Ventas

-4.1M

65M

BPA

-0.206

Margen de beneficios

-62.243

Empleados

304

EBITDA

-17M

-22M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+642.35% upside

Dividendos

By Dow Jones

Próximas Ganancias

11 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

13M

171M

Apertura anterior

6.8

Cierre anterior

0.78

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

174 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

ESPERION THERAPEUTICS INC Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

22 may 2025, 23:48 UTC

Acciones populares

Stocks to Watch: Deckers Outdoor, Intuit, Ross Stores, Lightbridge, NuScale Power, Centrus Energy

22 may 2025, 23:07 UTC

Principales Noticias

Fortescue Energy CEO to Resign in Executive Overhaul

22 may 2025, 23:03 UTC

Principales Movimientos del Mercado

Nuclear-Industry Stocks Get Boost After Report Says Trump Will Sign Orders to Jumpstart Field

22 may 2025, 23:59 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Lingering Worries Over U.S. Deficits -- Market Talk

22 may 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Trade in Range as Uncertainty Over Tariffs Continues -- Market Talk

22 may 2025, 23:45 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

22 may 2025, 23:23 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

22 may 2025, 23:23 UTC

Charlas de Mercado

Fortescue Iron Bridge Delay Disappoints; Executive Changes Welcomed -- Market Talk

22 may 2025, 23:12 UTC

Principales Noticias

Supreme Court Lets Trump Fire Agency Officials, but Moves to Protect Fed -- WSJ

22 may 2025, 21:54 UTC

Principales Noticias

Global Finance Officials Gloss Over Trade Tensions At G-7 Summit -- WSJ

22 may 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

22 may 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

22 may 2025, 20:46 UTC

Adquisiciones, fusiones, absorciones

Alcon and Lensar Receive FTC Requests for Additional Information About Merger

22 may 2025, 20:39 UTC

Ganancias

Tesla's Emissions Credits Are at Risk After Senate's California Vote -- Barrons.com

22 may 2025, 20:36 UTC

Principales Noticias

Antitrust Cops Say BlackRock, Other Fund Giants May Have Harmed Energy Competition -- 4th Update

22 may 2025, 20:36 UTC

Principales Noticias
Ganancias

Workday Logs Higher 1Q Revenue, Backs Outlook; Initiates $1B Buyback Program

22 may 2025, 20:32 UTC

Principales Noticias
Ganancias

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 may 2025, 20:27 UTC

Principales Noticias

Trump's 'Big, Beautiful Bill' Heads to Senate, Where New Fights Loom -- WSJ

22 may 2025, 20:20 UTC

Principales Noticias

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 may 2025, 20:17 UTC

Principales Noticias

The Deficit Is Unsettling Bond Traders. Here's How That Affects the Economy. -- 2nd Update

22 may 2025, 20:16 UTC

Ganancias

Intchains Group 1Q Rev $18.2M >ICG

22 may 2025, 20:15 UTC

Principales Noticias

Bond Market Shows Signs of Stabilizing; Nasdaq Rises -- WSJ

22 may 2025, 20:08 UTC

Principales Noticias
Ganancias

Intuit Stock Rises After Earnings Grew More than Expected In Latest Tax Season -- Barrons.com

22 may 2025, 20:05 UTC

Principales Noticias

Intuit Seeing Stable Environment for Consumers, Businesses While Tariffs Play Out

22 may 2025, 20:04 UTC

Ganancias

Workday Sees FY26 Subscription Revenue $8.8B >WDAY

22 may 2025, 20:04 UTC

Ganancias

Workday Sees 2Q Subscription Revenue $2.16B >WDAY

22 may 2025, 20:01 UTC

Ganancias

Intuit Sees FY25 EPS $13.19-EPS $12.24 >INTU

22 may 2025, 20:01 UTC

Ganancias

Workday 1Q Net $68M >WDAY

22 may 2025, 20:01 UTC

Ganancias

Workday 1Q EPS 25c >WDAY

22 may 2025, 20:01 UTC

Ganancias

Workday 1Q Adj EPS $2.23 >WDAY

Comparación entre iguales

Cambio de precio

ESPERION THERAPEUTICS INC previsión

Precio Objetivo

By TipRanks

642.35% repunte

Estimación a 12 Meses

Media 6.31 USD  642.35%

Máximo 16 USD

Mínimo 1.85 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para ESPERION THERAPEUTICS INC Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

6 ratings

4

Comprar

1

Mantener

1

Vender

Puntuación técnica

By Trading Central

0.85 / 1.05Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Strong Bearish Evidence

Sentimiento

By Acuity

174 / 382 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de ESPERION THERAPEUTICS INC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.